Pfizer Forecasts $54 Billion in 2022 Sales From Its Covid-19 Vaccine, Treatment – The Wall Street Journal

As Pfizer Inc. forecasts strong sales this year for its Covid-19 vaccine and treatment, the drugmaker is on the hunt for deals to bolster its pipeline of experimental products.

Pfizer said Tuesday that surging sales of its Covid-19 treatment and continued demand for its shots should boost the companys revenue to around $100 billion this year. The company estimated that sales of its antiviral pill Paxlovid will reach about $22 billion while the vaccine will add $32 billion.

Read the original here:

Pfizer Forecasts $54 Billion in 2022 Sales From Its Covid-19 Vaccine, Treatment - The Wall Street Journal

Related Posts
Tags: